A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults.

Trial Profile

A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2012

At a glance

  • Drugs Resiquimod (Primary)
  • Indications Warts
  • Focus Therapeutic Use
  • Sponsors 3M Pharmaceuticals; Graceway Pharmaceuticals
  • Most Recent Events

    • 31 Jan 2012 New trial record
    • 16 Feb 2007 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top